Paris-based Sanofi announced that the company’s Phase III PEGASUS clinical trial of rilzabrutinib for pemphigus failed to hit the primary or key secondary endpoints. Sanofi picked up the drug when the company acquired South San Francisco-based Principia Biopharma in August 2020 for $3.68 billion.
Shares of Forte Biosciences plunged after announcing that a Phase II atopic dermatitis trial assessing the company’s lead pipeline candidate failed to demonstrate statistical significance in the primary endpoint.
Japanese biopharmaceutical firm Takeda Pharmaceutical announced that the company’s drug candidate for leukemia failed to meet the primary endpoint in a late-stage study.
AC Immune and Genentech announced that their Phase II Lauriet trial of semorinemab in mild-to-moderate Alzheimer’s disease hit one of the study’s co-primary endpoints.
Belgium-based Bone Therapeutics’ Phase III osteoarthritis study using the company’s enhanced viscosupplement JTA-004 failed to meet primary and critical secondary endpoints.
Global biopharmaceutical firm Merck announced that the company’s Phase III trial for a potential treatment for pneumococcal disease in infants succeeded in meeting key safety, tolerability, and immunogenicity endpoints in the first 30 days.
Theravance announced that the diversified biopharmaceutical company’s oral drug candidate for the possible treatment of ulcerative colitis failed to meet the primary endpoint of a Phase IIb study.
Novartis said the company’s Kymriah CAR-T therapy did not meet the drug’s primary endpoint of event-free survival in a phase III study in patients with aggressive B-cell non-Hodgkin lymphoma (NHL) after relapse or lack of response to first-line treatment.
Junshi Biosciences announced that the Phase III clinical trial the Chinese pharmaceutical company is conducting alongside California-based Coherus BioSciences on a potential non-small cell lung cancer (NSCLC) drug is showing positive preliminary results.
Eli Lilly announced the success of the global health care company’s clinical trial on lebrikizumab as a treatment for people diagnosed with moderate to severe atopic dermatitis (AD).
